Business Wire

VERIMATRIX

5.6.2019 07:02:05 CEST | Business Wire | Press release

Share
Verimatrix and Ocilion Partner to Enable Secure, Future-Proof IPTV Delivery Across Austria

Verimatrix, the leader in redefining the standard for connected devices and services with an innovative combination of security and data analytics, and IPTV technology company Ocilion today announced two large Austrian operators as their latest customers. kabelplus and Salzburg AG have each selected on-premise IPTV solutions from Ocilion that are secured by Verimatrix, enabling more flexible and future-proof video delivery models.

Both operators opted independently for on-premise deployments hosted in their distinctive infrastructures, optimally suiting larger volumes of subscribers using Ocilion’s new homogenous P400 family of 4K set-top boxes (STBs), which combines innovation, design, functionality and efficiency. The advanced and adaptable technology offers the flexibility needed to support various delivery models, whether hybrid, FTTH or OTT, while the integrated Verimatrix client supports digital rights management (DRM) for IP, IP/DVB-C and OTT.

“kabelplus and Salzburg AG came to us with unique challenges and needs that will grow and evolve as consumer demands and security requirements continue to rapidly shift,” said Hans Kühberger, CEO of Ocilion. “We are very pleased to fulfil their demands for increasingly sophisticated modern and high-end IPTV services with our future-proof on-premise solution, including our new P400 family and resolve complex security requirements in partnership with Verimatrix.”

The decision for kabelplus, the largest cable network provider in Lower Austria and Burgenland, to launch its own IPTV product resulted from the need to extend its portfolio for its HFC network with extra products and services, and it came during the middle of a FTTH expansion and rollout. In need of a competitive edge to reinforce its position as a top service provider, kabelplus saw the Ocilion-Verimatrix partnership as the perfect fit to elevate its product portfolio with new premium features and bundling options.

When live-only DVB-C delivery was no longer enough to support Salzburg AG’s consumer demands, the Salzburg energy, transport and telecommunications provider turned to Ocilion and Verimatrix to set the foundation for it to be able to offer premium service enhancements and maximize upselling opportunities with long-term adaptability.

With these deployments, the Austrian operators are also laying the foundation for secure UHD ecosystems with OcilionsP400 line of STBs having officially received the Verimatrix 4.0 Ultra Security certification. This certification emphasizes their readiness to fully meet UHD security requirements, ensuring that they meet UHD content guidelines set by MovieLabs’ Specifications for Next Generation Video and Enhanced Content Protection.

“Achieving Ultra Security certification means that Ocilion’s advanced STBs are trusted to deliver premium content to kabelplus and Salzburg AG consumers at the highest quality possible and in accordance with the strongest security requirements specified by premium rights holders,” commented Verimatrix COO Steve Oetegenn. “Ultimately, the combined strengths of Ocilion and Verimatrix presents a formidable barrier against piracy in a form that can be updated readily to ensure these operators are able to keep pace with the evolving threat landscape.”

About Ocilion

Ocilion is a software company, providing individual end-to-end IPTV platforms to network providers in German-speaking Europe (Germany, Austria, Switzerland & Liechtenstein) since 2004. The white labelled IPTV platform is suited for all network topologies (HFC, FTTH, VDSL, OTT) and contains content, services, premium TV features (Replay, PVR, VoD), a full family of pre-integrated 4K set-top boxes and apps (smartphone, tablet, Apple TV, Amazon Fire TV). Operators can choose between on-premise systems (hosted in their distinctive infrastructure) and a rental option hosted by Ocilion (optimised for medium-sized carriers). Since 2009, the IPTV specialist started IPTV building solutions for hotels, hospitals, ships, corporate buildings and other projects (iptv500 product). For more information, visit www.ocilion.com .

About Inside Secure/Verimatrix

Inside Secure/Verimatrix (Euronext Paris – INSD) is redefining the standard for connected devices and services with an innovative combination of security and data analytics that maximizes revenues, protects reputations and enables growth. The company serves a range of industries and markets, including entertainment, mobile, computer networks and internet of things (IoT). The company offers easy-to-use software solutions, cloud services and silicon IP that provides unparalleled security and business intelligence. With more than 24 years of experience and a solid reputation, Inside Secure/Verimatrix protects customers’ most valuable content, transactions, applications, and communications. With 18 office locations in 12 countries supporting more than 1,200 customers, the company is uniquely positioned to secure and enable the connected future. For more information, visit www.insidesecure.com and www.verimatrix.com .

Contact:

Kelly Foster, Verimatrix +1 619 224 1261 kfoster@verimatrix.com

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Shilpa Medicare and Gate2Brain Sign Strategic Equity Partnership to Advance First-in-Class Brain Cancer Therapy8.6.2026 12:00:00 CEST | Press release

Shilpa Biocare Pvt Ltd, a Subsidiary of Shilpa Medicare Limited (BSE/NSE: SHILPAMED) has entered a strategic equity partnership with Gate2Brain, S.L., a biotechnology company focused on CNS therapeutics. Shilpa becomes a strategic shareholder and CMC, manufacturing, and regulatory partner for G2B-002 — Gate2Brain's lead program targeting deadly pediatric brain cancers, DIPG and pGBM, both with Orphan Drug Designation from the US FDA and EMA. G2B-002 uses Gate2Brain's proprietary MiniAp4 peptide shuttle to deliver SN-38 across the blood-brain barrier, demonstrating up to 100-fold greater brain drug transport preclinically. First-in-human trials are anticipated by FY28. G2B-002 targets high-growth oncology markets — the glioblastoma market projected at USD 6.48B by 2035 (CAGR: 7.97%), pediatric brain tumors at USD 2.47B by 2031 (CAGR: 6.9%), and DIPG at USD 1.2B by 2035 (CAGR: 7.1%). Gate2Brain's MiniAp4 platform further extends potential across rare pediatric cancers and broader CNS cat

Haleon Invests in India to Deliver Better Everyday Health to Rural Communities8.6.2026 11:11:00 CEST | Press release

£175m for first Haleon manufacturing site in Madhya Pradesh, central IndiaFast-growing India key to Haleon reaching one billion more consumers by 2030India’s consumer health market to reach over £23bn by 20301Accelerated rural distribution to access 3 million outletsAffordable Sensodyne packs and investment to double ‘last-mile’ reach in rural areas Haleon, a consumer company that is solely focused on better everyday health, today announces plans to expand its business in India, one of its fastest-growing markets and key to Haleon delivering its strategy and ambitions to reach one billion more consumers by 2030. Haleon will invest approximately £175 million2 in building a new oral health manufacturing site in Madhya Pradesh, central India and accelerate distribution efforts in rural India to meet rising demand. The new site will also support supply for wider Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608753094/e

Diabetology’s Breakthrough Clinical Data From Oraglutide™ Oral GLP-18.6.2026 10:56:00 CEST | Press release

Oraglutide™ Once Weekly, Low Dose, Low side-effect, Oral GLP-1 Glucose and Insulin Response Over 6 days: Clinical Data Posted at World ADA Diabetes & Obesity Conference Diabetology Limited (Jersey) poster presentation (https://diabetology.co.uk/ada-poster) 1724-P at the ADA 86th Scientific Session, New Orleans, reporting first human data from Oraglutide™ — small capsule intestinally-released oral semaglutide, formulated using the proprietary Axcess™ delivery technology. KEY HIGHLIGHTS 6-day glucose control: A single 4 mg oral dose of Oraglutide™ produced a sustained fall in glucose. Measuring 14% at Day 6 (p=.046), the longest duration presented from a single oral GLP-1 dose in a human IVGTT study. 28% increase in insulin secretion: Relative to placebo, insulin percent AUC increased by 12% day 0, (p=0.02) & 28% Day 1 (p = 0.025). Novel intestinal depot effect: Blood levels of semaglutide were higher on Day 1 than dosing on Day 0, consistent with lipid associated depot effect in the int

Reply at VivaTech 2026: Making AI, Agents and Robotics Happen Across the Enterprise8.6.2026 10:00:00 CEST | Press release

Reply[EXM, STAR: REY] is taking part in VivaTech 2026, Europe's largest innovation and technology event, held from June 17 to 20 at Paris Expo Porte de Versailles. At the event, Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608667672/en/ At VivaTech 2026 Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. Industries are being reshaped by AI, autonomous agents, robotics and new digital experiences. From strategy to execution, Reply helps companies move beyond experimentation and innovative ideas into concrete business value. Visitors can meet Reply in Hall 7.1, booth 1G12, and explore how, through real use cases, scalable solutions and live demonstrations, the group makes innovation happen. This year, Reply'

Cardiolife Partners with Bhutan Ministry of Health to Strengthen Nationwide Cardiac Care8.6.2026 10:00:00 CEST | Press release

Cardiolife is proud to partner with the Ministry of Health of Bhutan to roll out its advanced AI-powered ECG diagnostics system nationwide. The collaboration will provide access to early ECG diagnosis and prevention, marking a major step forward in the country’s effort to strengthen heart health and preventive care. Bhutan has a population of just over 700,000 people and heart failure and other cardiac conditionsare among the leading causes of death. Following constructive meetings in Thimphu, His Excellency, the Health Minister, officially endorsed the national rollout of Cardiolife’s solution and expressed appreciation for Cardiolife’s commitment to advancing cardiac care through the provision of free software and ECG equipment in Bhutan. “We are grateful to the Cardiolife team for their commitment to improving heart health in Bhutan. With cardiovascular diseases on the rise, this collaboration marks an important milestone in our journey to strengthen early detection and prevention a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye